Texas Rangers to Add Justin Foscue to Roster following Jung's Injury

https://icaro.icaromediagroup.com/system/images/photos/16141152/original/open-uri20240402-18-gy2l20?1712098233
ICARO Media Group
News
02/04/2024 22h45

In a bid to fill the void left by an injured first-round draft pick, the Texas Rangers have announced their decision to bring up Justin Foscue to the roster. This move comes after Jung suffered a fractured wrist during Monday's game against Tampa Bay, forcing him to be placed on the injured list.

Sources close to the team revealed that Foscue, the 2020 first-round draft pick, will make his debut for the Rangers on Tuesday's game against Tampa Bay. The club has high hopes for the 25-year-old prospect, who is touted as having the ability to fill Jung's offensive capabilities.

Although Foscue had a modest performance in Triple-A Round Rock's opening weekend series against Sugar Land, going 3 for 13 with a pair of walks, his impressive minor league OPS of .879 over 285 games prior to this season reflects his potential as a valuable addition to the team.

The biggest question surrounding Foscue's role is how the Rangers will utilize him on the field. While he has experience playing at third base, Foscue spent more time honing his skills at first base during spring training. It is likely that he will be the right-handed platoon partner to Jared Walsh at first base, while Ezequiel Duran moves over to third base.

Furthermore, it is expected that Duran will platoon with left-handed hitter Josh Smith at third base, providing the Rangers with the flexibility to optimize their lineup against different pitchers throughout the season.

Rangers fans will undoubtedly be eager to see Foscue in action and witness how he contributes to the team's offensive prowess. With Jung's unfortunate injury, Foscue's arrival brings a glimmer of hope and excitement to the Texas ballclub.

Stay up to date with the latest news and be the smartest Rangers fan in town.

The views expressed in this article do not reflect the opinion of ICARO, or any of its affiliates.

Related